PJSIMP
MBRX icon

P.J. Schmidt Investment Management (PJS)’s Moleculin Biotech MBRX Stock Holding History

P.J. Schmidt Investment Management (PJS)’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-77
Closed -$14.1K – 182
2023
Q4 		$14.1K Hold
77
– – ﹤0.01% 170
2023
Q3 		$17.8K Hold
77
– – ﹤0.01% 167
2023
Q2 		$19K Buy
+77
New +$20.3K ﹤0.01% 170

Other funds holding MBRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AWM
Atticus Wealth Management Palm Beach Gardens, Florida $420M AUM 23.31% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FIM
FWL Investment Management Dallas, Texas $456M AUM 60.63% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

P.J. Schmidt Investment Management (PJS)'s MBRX Position: Q1 2024 in Review

P.J. Schmidt Investment Management (PJS) sold out of Moleculin Biotech (MBRX) in Q1 2024, closing a stake of 77 shares — an estimated $14.1K sold.

P.J. Schmidt Investment Management (PJS) first reported a position in MBRX in Q2 2023 and held it in 3 quarters. The position peaked at $19K in Q2 2023. 15 funds tracked by Wall St. Rank hold MBRX as of Q1 2024.

  • P.J. Schmidt Investment Management (PJS) reported no remaining Moleculin Biotech position as of Q1 2024 after selling out during the quarter.
  • P.J. Schmidt Investment Management (PJS) sold 77 Moleculin Biotech shares in Q1 2024, an estimated $14.1K.
  • P.J. Schmidt Investment Management (PJS) first reported a position in Moleculin Biotech in Q2 2023 and held it in 3 quarters.
  • P.J. Schmidt Investment Management (PJS)'s Moleculin Biotech position peaked at $19K in Q2 2023.
  • 15 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2024.

Based on P.J. Schmidt Investment Management (PJS)'s 13F filing for Q1 2024, filed 26 Apr 2024.